---
title: "AMLX.US (AMLX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AMLX.US/news.md"
symbol: "AMLX.US"
name: "AMLX.US"
parent: "https://longbridge.com/en/quote/AMLX.US.md"
datetime: "2026-03-10T04:32:10.911Z"
locales:
  - [en](https://longbridge.com/en/quote/AMLX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AMLX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AMLX.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AMLX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AMLX.US/news.md)


# AMLX.US (AMLX.US) — Related News

### [Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded by Wall Street Zen to Hold Rating](https://longbridge.com/en/news/278205527.md)
*2026-03-07T08:19:24.000Z*
> Wall Street Zen upgraded Amylyx Pharmaceuticals (NASDAQ:AMLX) from a "sell" to a "hold" rating. Other analysts have mixe

### [Q1 EPS Forecast for Amylyx Pharmaceuticals Lifted by Analyst](https://longbridge.com/en/news/278095132.md)
*2026-03-06T12:13:31.000Z*
> Research analysts at HC Wainwright have raised their Q1 2026 earnings per share (EPS) forecast for Amylyx Pharmaceutical

### [The Bull Case For Amylyx Pharmaceuticals (AMLX) Could Change Following Narrower Losses And New Shelf Filings](https://longbridge.com/en/news/277799994.md)
*2026-03-04T14:57:04.000Z*
> Amylyx Pharmaceuticals reported a narrowed net loss of $33 million for Q4 2025, down from $37.55 million a year prior, a

### [Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout](https://longbridge.com/en/news/277751027.md)
*2026-03-04T08:57:51.000Z*
> Amylyx Pharmaceuticals (NASDAQ: AMLX) executives highlighted potential milestones for the company during the TD Cowen’s 

### [Amylyx Pharmaceuticals | 10-K: FY2025 Revenue: USD 0](https://longbridge.com/en/news/277618274.md)
*2026-03-03T12:13:24.000Z*
### [Amylyx Pharmaceuticals Q4 net loss beats estimates](https://longbridge.com/en/news/277617490.md)
*2026-03-03T12:08:08.000Z*
> Amylyx Pharmaceuticals reported a Q4 net loss that exceeded analyst expectations, with a loss per share of $0.30 compare

### [This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday](https://longbridge.com/en/news/277616187.md)
*2026-03-03T11:57:38.000Z*
> Top Wall Street analysts have initiated coverage on several companies with positive outlooks. Stifel's James Condulis ra

### [A Look at Amylyx Pharma's Upcoming Earnings Report](https://longbridge.com/en/news/277500065.md)
*2026-03-02T17:01:20.000Z*
> Amylyx Pharma (NASDAQ:AMLX) is set to release its quarterly earnings on March 3, 2026, with analysts expecting an EPS of

### [GSA Capital Partners LLP Sells 118,426 Shares of Amylyx Pharmaceuticals, Inc. $AMLX](https://longbridge.com/en/news/276532620.md)
*2026-02-22T10:21:13.000Z*
> GSA Capital Partners LLP has reduced its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 69.4%, selling 118,426 s